Business
Notice of Interim Results
Notice of Interim Results.
About this update from Skinbiotherapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 1300F SkinBioTherapeutics PLC 16 February 2018 \n\nSkinBioTherapeutics plc\n \nNotice of interim results \n \nManchester, UK - 16 February 2018 - SkinBioTherapeutics plc (AIM: SBTX or the \"Company\") a life sciences company focused on skin health, will publish its interim results for the six months to 31 December 2017 on 21 February 2018.\n \nThe information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 and has been arranged for release by Doug Quinn, CFO of the Company.\n \n-Ends-\nFor more information, please contact: \n \n\n\n\n\nSkinBioTherapeutics plc\nDr. Cath O'Neill, CEO\nDoug Quinn, CFO \n \n\n\nTel: +44 (0) 161 468 2760\n\n\n\n\nCairn Financial Advisers LLP (Nominated Advisor)\nTony Rawlinson / Emma Earl / Richard Nash\n \n\n\nTel: +44 (0) 20 7213 0880\n\n\n\n\nTurner Pope Investments (Joint Broker)\nBen Turner / James Pope\n \nNorthland Capital (Joint Broker)\nJohn Howes / Tom Price \n \n\n\nTel: +44 (0) 20 3621 4120\n \n \nTel: +44 (0) 20 3861 6625\n\n\n\n\nInstinctif Partners\nMelanie Toyne-Sewell / Deborah Bell \n\n\nTel: +44 (0) 20 7457 2020\[email protected] \n\n\n\n\n \n \nNotes to Editors\n \nAbout SkinBioTherapeutics plc\nSkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Cath O'Neill and Professor Andrew McBain. \nSkinBioTherapeutics' platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models. Proof of principle studies have shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas. \nSkinBioTherapeutics received seed funding from the Tech Transfer office of the University of Manchester for the discovery of SkinBiotix®. The platform was subsequently spun out of the University of Manchester in March 2016 and was funded by OptiBiotix PLC (AIM: OPTI).\nThe Company joined AIM in April 2017 concurrent with raising £4....